American tegumentary leishmaniasis (ATL) is highly endemic in the state of Amazonas (AM), Brazil. According to the Information System on Notifiable Diseases database, 18,675 Brazilian cases were reported in 2013, 8% of which occurred in the city of Manaus, AM ([@B22]). In this region, control of the disease is considered difficult because of the epidemiological characteristics and socioeconomic conditions associated with the sylvatic transmission cycle. In addition, environmental changes may influence infection dynamics, which makes control even more difficult. The circulation of at least seven *Leishmania*species has been observed in ATL in the Amazon Region. *Leishmania (Viannia) guyanensis*is the most prevalent species and is highly endemic in north of the Amazon River ([@B15], Grimaldi Jr et al. 1991, [@B13], [@B18], [@B20],[@B10]). In this sense, several studies have shown that the frequency of circulating species in this area varies ([Table I](#t1){ref-type="table"}) and that *Leishmania (V.) naiffi* seems to be more consistently isolated from cutaneous lesions in patients from this region.

TABLE IFrequency of *Leishmania*species associated with American tegumentary leishmaniasis in Amazon Region*Leishmania*speciesCases (n)Relative proportion within the study (%)Region of endemicity state (city)Reference*L. (Viannia) guyanensis*6164.9Amapá, Amazonas, Pará and RondôniaGrimaldi Jr et al. (1991)*L. (V.) braziliensis*1516  *L. (V.) naiffi*1010.6  *L. (Leishmania) amazonensis*66.4  Not identified22.1  *L. (V.) guyanensis*6997.2Amazonas (Manaus)Romero et al. (2002b)*L. (V.) braziliensis*22.8*L. (V.) braziliensis*1653.3Acre (Rio Branco)da [@B5]*L. (V.) lainsoni*1240*L. (V.) guyanensis*13.3  Hybrid:*L. (V.) lainsoni/L. (V.) naiffi*13.4  *L. (V.) guyanensis*1076.9Amazonas (Manaus)Figueira et al. (2008)*L. (V.) naiffi*323.1*L. (V.) guyanensis*880Amazonas (Rio Preto da Eva)Figueira et al. (2008)*L. (V.) naiffi*220*L. (V.) guyanensis*8089Amazonas (Rio Preto da Eva)Figueira et al. (2014)*L. (L.) amazonensis*77.8*L. (V.) naiffi*33.3*L. (V.) braziliensis*1125.6Pará (lower Amazon Region)Jennings et al. (2014)*L. (V.) guyanensis*613.9*L. (V.) shawi*49.3*L. (V.) shawi*716.3*L. (V.) lainsoni*613.9*L. (L.) amazonensis*24.7Hybrid:*L. (V.) guyanensis/ L. (V.) shawi shawi*716.3

*L. (V.) naiffi*was first described by [@B12] after being isolated from an armadillo (*Dasypus novemcinctus*) in the state of Pará, northern Brazil. The few cases described in the literature usually associate *L. (V.) naiffi*with low rates of virulence in humans*.*Thus, it has been described that the disease evolves with a benign clinical course and a good response to treatment ([@B14], [@B17]). Furthermore, two cases of spontaneous healing of leishmaniasis caused by *L*.*(V.) naiffi* were described ([@B23]). To date, however, no association between *L. (V.) naiffi* and mucosal leishmaniasis has been observed. *L. (V.) naiffi* cutaneous leishmaniasis lesions are usually ulcerated, unique, small and located on the hands, arms or legs ([@B14]). In the same way, experimental studies have shown that *L. (V.) naiffi* frequently causes discrete or even nonapparent infections on hamsters' skin ([@B12]). These findings were supported by in vitro analysis, which demonstrated that *L. (V.) naiffi* showed the lowest infection index and the highest nitric oxide production compared with other species of the *Viannia* subgenus ([@B2]. Then, the clinical and experimental information previously reported supported the idea that infection by *L. (V.) naiffi* commonly results in benign manifestations. Therefore, the present study aimed to strengthen the awareness of the clinical and epidemiological importance of *L. (V.) naiffi* in the Amazon Region and to report therapeutic failure associated with this species.

Thirty *Leishmania* spp samples were isolated from cutaneous lesions of patients from different surrounding areas of Manaus. Samples were collected during 2011-2013 at the Heitor Vieira Dourado Tropical Medicine Foundation (FMT-HVD), a reference centre for tropical diseases in AM. Skin lesion fragments obtained by biopsy were cultured in Novy-Neal-Nicolle medium and *Leishmania* was isolated. Parasites were sent to the *Leishmania* Collection from the Oswaldo Cruz Institute for species identification. This study was approved by the Research Ethical Committee of FMT-HVD (protocol 21273572). Identification of *Leishmania*spp isolates was based on multilocus enzyme electrophoresis (MLEE) and performed on agarose gel and allelic variations were tested for the following enzymes: 6-phosphogluconate dehydrogenase (EC1.1.1.44), glucose-6-phosphate dehydrogenase (E.C.1.1.1.49) and isocitrate dehydrogenase (E.C.1.1.1.42). The method was performed in accordance with the conditions described by [@B4].

Four species were identified: *L. (V.) guyanensis* 66.7% (20/30),*L. (V.) naiffi* 26.7% (8/30), *Leishmania (Leishmania) amazonensis* 3.3% (1/30) and *Leishmania (V.) shawi* 3.3% (1/30). As expected, the most common species was *L. (V.) guyanensis*. Surprisingly, none of the isolates were characterised as *L. (V.) brazi- liensis*. According to Romero et al. (2002b), cases of ATL caused by*L. (V.) braziliensis* are uncommon in nearby Manaus. Interestingly, the frequency of *L. (V.) naiffi* was 26.7% (8/30), which indicates that this species could be an etiologic agent of CL more frequent than expected in this region. These data corroborate those obtained by [@B8], who observed a relevant number of CL associated with*L. (V.) naiffi* in the municipalities of Rio Preto da Eva and Manaus.

Several methods have been used to define *Leishmania* species ([@B6], [@B18], [@B3]). Nevertheless, MLEE remains one of the main tools for characterising*Leishmania* because it reveals polymorphisms that express phenotypes of population variations and taxonomically classify the different species of this parasite ([@B4]). Precise identification of *Leishmania*spp is fundamental to understanding the disease's epidemiology; improving the current knowledge concerning its pathology and the control measures ([@B3]). Thus, it is likely that the transmission of *L. (V.) naiffi* in the Amazon Region is more frequent than has been reported. In this connection, the CL patients infected by*L. (V.) naiffi* (n = 8) are described below. All of them were men with a mean age of 37.4 ± 13.7 years (median = 37.5 years). The mean days of duration was 30 ± 24.8 days \[median = 30 days (95% confidence interval: 22.5 - 52.5)\]. The number of lesions ranged from one-four. Four subjects were initially treated with antimonial and four individuals were initially treated with pentamidine (antimonial: 10-20 mg Sb^+5^/kg/day for 20/30 consecutive days; pentamidine: 3 doses of 4 mg/kg with an interval of 72 h between doses) ([Table II](#t2){ref-type="table"}). Two of the patients experienced a poor response to antimonial or pentamidine therapy.

TABLE IIDemographic and clinical data of patients infected with*Leishmania (Viannia) naiffi*Patient IDGenderAgeLesions (n)Location of lesionDisease durations (days)Presence of amastigotesTreatmentOutcome1M361Upper limb30+Antimonial (20 days) + antimonial (30 days)Failure2M391Lower limb90+Pentamidine (3 doses) + pentamidine (3 doses)Failure3M591Upper limb60+Antimonial (20 doses)Cure4M301Upper limb15+Antimonial (20 doses)Cure5M294Upper limb20+Pentamidine (3 doses)Cure6M392Lower limb30+Pentamidine (3 doses)Cure7M522Face30+Antimonial (20 doses)Cure8M151Lower limb30+Pentamidine (3 doses)Cure[^1]

Previous studies have suggested that the *Leishmania* species and the endemic area examined can be influenced by the cure rate (Romero et al. 2001b, [@B1]). In a recent study conducted in AM, the cure rates in *L. (V.) guyanensis*infection after treatment with antimonial or pentamidine were 55.5% and 58.1%, respectively ([@B16]). To date, all of the studies described in the literature have associated infection by *L. (V.) naiffi* with spontaneous healing or a good therapeutic response. However, the data obtained by our group showed therapeutic failure in a patient who was infected by *L. (V.) naiffi*and treated with pentamidine (R Vieira-Gonçalves, unpublished observations). Corroborating this finding, we herein illustrate two new CL cases that are associated with*L. (V.) naiffi*infection and presented pentamidine or antimonial-resistant lesions ([Table II](#t2){ref-type="table"}), which indicates that the clinical evolution of infection from this species may not be as favourable as described. No cases of spontaneously healing was seem probably because the short period of disease duration until the diagnosis establishment. The cases of *L. (V.) naiffi*reported herein underline that this species may not have a self-limiting nature, as previously described ([@B14], van der Snoek et al. 2009), and could not be as uncommon as referenced (Grimaldi Jr et al. 1991,[@B7]). The present results highlight the importance of characterising *Leishmania* spp in areas that exhibit a sympatric circulation of *Leishmania* spp parasites to define the epidemiological importance of each of these species to human disease. This knowledge can improve the surveillance and therapeutic approaches used to achieve a clinical cure.
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[^1]: M: male; +: positive smears of scarifications.
